What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2353.png

 

Symptoms Control

 

MPN’s symptomatic burden affects patient’s health-related quality of life and daily routines1

 

Some of Prevalent symptoms in MF2

Fatigue

 

Frame 427318883.png

98.9%

Inactivity

 

Frame 427318882.png

76.5%

Early satiety

 

Frame 427318881.png

75.5%

Insomnia

 

Frame 427318880.png

73.9%

 

Concentration difficulties

 

Frame 427318887.png

72.5%

 

Abdominal discomfort

 

Frame 427318886.png

71.7%

 

Abdominal pain

 

Frame 427318885.png

63%

Weight loss 

(Constitutional symptom)

Frame 427318884.png

48.9%

Adapted from ref2

Symptom burden impairs activity and productivity1

Patients experiencing effect of symptoms upon daily activities

Cancelling planned 
activitiesa

 

Frame 427318891.png

 

41% 
n=207

Staying all/most 
of day in beda

 

Frame 427318890.png

 

32% 
n=207

Requiring reduced 
working hoursb

 

Frame 427318889.png

 

59% 
n=119

Taking days off work 
due to sicknessa

 

Frame 427318888.png

 

29 % 
n= 52

a In the preceding 30 days 
b Respondents employed full- or part-time only

Patients receiving ruxolitinib show improvements in myelofibrosis-associated symptoms3

COMFORT-II: Mean change in EORTC QLQ-C30 symptom scores3

 

Layer_11.png

 

MPNs: Philadelphia-chromosome negative myeloproliferative neoplasms

For JAKAVI-MF Abbreviated prescribing information

PDF
View

References

  1. Mesa R, Miller CB, Thyne M,et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC cancer. 2016;16(1):1-0. 

  2. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): 
    International Prospective Validation and Reliability Trial in 402 patients. Blood. 2011; 01-328955 

  3. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine. 2012 Mar 1;366(9):787-98.

Approved by Egyptian Drug Authority: HF0424OA4703/102025. Invalidation date: 17/12/2025.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.

Jakavi QR

HF0424OA4703/102025 17/12/2025

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting